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Aim.T oi n v e s t i g a t ee ﬃcacy and tolerability of Silicea Gastrointestinal Gel in patients with gastrointestinal disorders. Methods.
Open, prospective pivotal phase IV study with oral Silicea Gastrointestinal Gel over 6 weeks. Symptom score was part 1 of the
Nepean Dyspepsia Index: 15 questions addressing intensity, frequency and impact of upper abdominal symptoms. 10 lower
abdominal symptoms were asked analogously. A responder showed reduction of score of >50%. Results. 62 of 90 patients were
evaluated per protocol. Upper and lower abdomen sum scores decreased already in the ﬁrst three weeks (P<0.001), which
continuedthefollowingthreeweeks(P<0.01).Meansymptomscoreforupperabdomendecreasedfrom52.2±31.0t o33.7±28.7
(or by 35.4%; responder rate 37%); for lower from 39.6 ± 24.7t o2 2 .6 ± 21.7 (by 42.9%; responder rate 46%). Subgroups with
diarrhea, IBS and GERD presented highest responder rates. 6% of patients reported adverse reactions with probable or possible
relationship to the test product. Conclusions. Silicea Gastrointestinal Gel seems suitable beyond infectious acute gastrointestinal
disorders. Responses are relevant for chronic functional disorders, but it remains unclear, how much of that might be placebo-
eﬀect. Controlled studies are recommended in gastrointestinal syndromes like IBS or GERD.
1.Introduction
About 20–30% of people in the western world experience
chronic gastrointestinal complaints relating to functional
bowel disorders [1], half of those seeking medical attention
[2, 3].
The spectrum of symptoms such as pain, nausea, emesis,
distension, ﬂatulence, and diarrhea is linked to various con-
ditions, from acute infections to chronic dysfunctions. After
exclusion of a somatic disorder, such chronic symptoms are
usually categorized as either nonulcer dyspepsia (NUD) or
irritable bowel syndrome (IBS). Comorbidity, respectively,
consecutiveappearanceofbothentitiesisfrequent.However,
the diagnosis can be challenging particularly because of
variability and overlap of symptoms [4]. Functional gas-
trointestinal complaints are often treated with drugs such as
proton pump inhibitors (PPIs) or prokinetics. The overlap
of upper and lower GI symptoms might explain why PPIs do
not provide complete symptom relief in patients with GERD
[5] (gastroesophageal reﬂux disease) and corresponding
improvement in health-related quality of life [6]. But PPIs
might also induce gastrointestinal symptoms, especially after
stopping therapy [7].
10–15% of the western world is aﬀected by IBS [8, 9]
and about 5% seeks medical attention. IBS is associated with
high direct and productivity costs. The prevalence of simple
constipation is also as high as 15% in North America [10].
Interpreting eﬃcacy studies in functional dyspepsia is
diﬃcult since a variety of test instruments are used, many of
which have not been validated. Additionally, most patients
continue to self-treat with over-the-counter medication.
Some herbal products have been shown to be helpful in
treating gastrointestinal problems [11], and some of these
studies have been conducted in comparison with standard
prokinetic drugs [12]. For many other over-the-counter
medications, research about use, beneﬁt, and risk is lacking.2 Gastroenterology Research and Practice
Evidence of eﬃcacy of IBS drug therapies with bulking
agents,antispasmodics,andantidepressantsisweak,particu-
larly because of the problem of valid outcome measures [13].
Silicea Gastrointestinal Gel is classiﬁed as a Class IIa
medical device in Germany due to the fact that it is not
absorbed during digestion. 100mL of the silicon gel contain
3.5g silicon dioxide (silica). The silicon dioxide is mixed
with water to form a gel. Molecules (acids, ions, organic
poisons, gas, and bacteria) are adsorbed to this structure.
Silicic acid is also extremely hygroscopic; therefore also water
molecules bind to the primary hydrophilic adsorption sites.
This enables silica gel to have very large surface areas. For
example, a surface area of 300m2/g has been measured, with
ap a r t i c l es i z eo f3 . 5t o4 . 5µm. A structure with secondary
channels as adsorption cavities has been described as a
treatment for infectious diarrhea. Relevant binding capacity
was found for staphylococcal enterotoxin C1 and bacteria (E.
coli), which was comparable to that of activated carbon, and
was not aﬀected by acidic pH [14]. Taking into consideration
the negative charge of the silicon dioxide particles and
predominantly negative charge of the bacteria surfaces,
the high binding capacity for bacteria may be explained
by ﬂocculating aggregation via bridge-building anorganic
cations. The silica gel structure binds water and is not
aﬀected in the upper intestinal tract. Furthermore silicic acid
couldprovidelocalprotectiontothegastrointestinalmucous
membrane. Clinically, decrease in duration of diarrhea, stool
frequency [15], abdominal pain, distension, nausea, and
vomiting has been described [16]. It is currently unknown,
however, which gastrointestinal symptoms respond best to
silica gel and whether acute or chronic symptoms may be
inﬂuenced by this treatment.
2.MaterialsandMethods
2.1. Ethics. This work has been carried out in accordance
withtheDeclarationofHelsinki(2000)oftheWorldMedical
Association. Since this was an observational study of an
over-the-counter product, ethics committee approval was
not necessary. Patients signed informed consent to electronic
processing of their pseudonymized data.
2.2. Patients. 90 outpatients of the ambulance of the Natur-
opathic Department with gastrointestinal complaints were
included in this observational study. Inclusion criteria were
at least 2 of the following symptoms with moderate or
greater intensity and frequency during at least 5 of the
previous 14 days: bad breath, eructation, nausea, heart burn,
stomach discomfort, epigastric pain, diarrhea, hypogastric
pain, or spasms. Patients suspected clinically to have organic
problems were not included unless procedures for exclusion
of organic problems were being performed. Patients who
changed medication or diet for their gastrointestinal com-
plaints or with relevance to gastrointestinal functions during
the 12 weeks prior to the study or during the study were also
not included and not evaluated, respectively. Additionally,
patients with diseases that might have inﬂuenced symptoms
and pregnant or nursing women were not included.
2.3. Medication. Silicic acid is an inert adsorption agent
that has been used for many years in the treatment of
gastrointestinal disorders. It is currently marketed as Sil-
icea Gastrointestinal Gel (manufacturer: Anton H¨ ubner &
Co KG) and Sikapur Gastrointestinal Gel (manufacturer:
Medopharm GmbH).
At the beginning of treatment, patients were advised to
take two 15mL spoonfuls of gastrointestinal gel dissolved in
water or tea 3 times daily at least 2 hours after the last meal
or before lunch, dinner, and bedtime, respectively, breakfast.
After 3 days, treatment was continued with one 15mL
spoonful three times a day.
2.4. Course of Study. Inclusion of patients was based on
individual case history and a physical examination. Patients
completed questionnaires about gastrointestinal symptoms
at the time of inclusion (visit 0), after 3 weeks (visit 2),
and after 6 weeks (visit 3). There was also a telephone
interview one week (visit 1) after inclusion. Tolerability and
compliance were recorded over this 6-week period. Stool
behavior and gastrointestinal symptoms were recorded in a
patient’s diary.
Patients were informed about the test drug, its adminis-
tration, and how to document consumption, gastrointestinal
symptoms, and bowel habits in the diary. They were ex-
plicitly instructed to not change their diet during the study.
Diet was surveyedusing a qualitative questionnaire at the be-
ginning and end of the study. Patients were also weighed at
the beginning and end. After 6 weeks, patients were again
asked about their condition, medications, and any adverse
reactions. Drug tolerability was rated, and physical examina-
tions were repeated. The remaining test drug was weighed as
a measure of compliance.
2.5. Evaluation Parameters. The primary outcome measure
was the change in gastrointestinal symptom score according
to a modiﬁed Nepean Dyspepsia Index. This score (part I
of the validated Nepean Dyspepsia Index [17]) comprised
15 questions related to symptoms of the upper abdomen
with points to be summed up from their intensity, frequency,
and impact on quality of life with regard to the previous
two weeks. We added 10 analogous questions related to
symptoms of the lower abdomen. Scores were calculated
as the sum of the symptoms for upper abdomen or lower
abdomen and total score as the sum of both scores.
2.6. Statistical Analysis. All data were evaluated in a descrip-
tive manner. All data are presented as means ± SE. Changes
in sum scores were analyzed with two-tailed, paired t-tests.
3. Results
3.1. Patients. 90 outpatients were included in the study
(64 females, 26 males; mean age 56.5 years (range 19–72);
mean body mass index 24.1 (range 17.1–35.0kg/m2)). The
most common symptoms were abdominal distension (27
patients), heartburn (21 patients), abdominal cramps (11
patients), and diarrhea (10 patients). Other complaints wereGastroenterology Research and Practice 3
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Figure 1: Patients ﬂow chart.
nausea (6 patients), epigastric pain (6 patients), and other
symptoms (5 patients). 8 patients were smokers, and 34
patients consumed alcohol more than once a week. Physical
examination and vital parameters (heart rate and blood
pressure) showed no relevant abnormalities. 38 patients
received continuous therapy for gastrointestinal symptoms:
12 patients took proton pump inhibitors, 8 took antacids, 4
took acid blockers, 4 took herbal medicines, and 10 others.
67 patients took various other medications (9 patients
NSAIDs and 6 thyroid hormones). Change of other non-
gastrointestinal medications was reported in 1 patient after
1 week, in 8 patients after 3 weeks.
During the course of the study, 23 patients dropped out.
4 of these patients stopped because of travelling, 4 patients
dropped out without giving reason, and 1 patient had an ex-
clusion reason which was not documented in V1, 11 pa-
tients stopped treatment due to adverse eﬀects (3 of which
had a probable relation to the test product), 1 patient due
to SUE not related to test product, and 2 patients stopped
due to insuﬃcient eﬃcacy. 5 patients did not complete the
visit 2 questionnaire. Overall, 62 per-protocol-patients were
analyzed for eﬃcacy (see Figure 1).
3.2.Outcome. Themeanscorefortheupperabdomensymp-
toms decreased after 6-week treatment from 52.2 ± 31.0t o
33.7 ± 28.7 and the mean score for the lower abdomen
0
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Upper abdomen
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Figure 2: Mean of total symptom score, upper abdomen score, and
lower abdomen score in the course of the study: standard error of
the mean (n = 62).
decreased from 39.6 ± 24.7t o2 2 .6 ± 21.7. The total
gastrointestinal score decreased from 91.8 before therapy to
56.3 after the 6-week treatment (see Figure 2).
Reductions of symptom scores are highly signiﬁcant as
shown in Tables 1 and 2.
Due to the wide range in severity between patients, anal-
ysis looked also for relative changes. Mean relative reduction4 Gastroenterology Research and Practice
Table 1: Changes of symptom scores for upper abdomen, and lower abdomen (mean, standard deviation, minimum, maximum, P value
2sided Wilcoxon-test).
N Mean SD Min Max P value
V2 (day 21)–V0 upper abdomen 62 10,9 25,0 −40 92 <0.002
V3 (day 42)–V2 (day 21) upper a. 62 7,7 21,2 −51 77 <0.003
V3–V0 upper abdomen 62 18,5 26,6 −26 91 <0.001
V2 (day 21)–V0 lower abdomen 62 12,1 18,0 −32 57 <0.001
V3 (day 42)–V2 (day 21) lower a. 62 4,9 14,0 −32 44 <0.003
V3–V0 lower abdomen 62 17,0 19,5 −27 65 <0.001
Table 2: Relative changes between V0 and V3 (mean, standard deviation, minimum, maximum, responder frequency).
n mean (%) sd min max Responders
Total score 62 38 35.4 − 33 97 24 (39%)
Upper abdomenscore 59(1) 30 61.4 −250 100 22 (37%)
Lower abdomen score 61(1) 42 42.2 − 62 100 28 (46%)
(1)Patients with no complaints for one domain omitted.
was 30% for upper abdominal symptom score and 42% for
lower abdominal symptom score. 37% of the patients were
responders (>50% reduction of scores) with regard to upper
abdominal complaints, and even 46% with regard to lower
abdominalcomplaints(and39%forthetotalgastrointestinal
score).
Patientsthenwerecategorizedaccordingtotheirprimary
complaint at the initial visit as either “upper abdominal” (34
patients) or “lower abdominal” (32 patients). 4 patients had
high scores for both categories and were therefore placed in
bothgroups.Othersubgroups(withsomeoverlapofpatients
attributed to several subgroups) are shown in Figure 3.
In addition, patients with severe ﬂatulence were sepa-
rated nonexclusively into “upper abdominal gas” (29 pa-
tients) and “lower abdominal gas” (22 patients) subgroups.
In the upper-abdominal group of symptoms, eructation
and upper-abdominal cramps did not improve as much
as other symptoms. Improvement of heartburn mainly oc-
curred later than other symptoms between week 3 and 6
of the study; 14 out of 34 (upper abdominal) patients
could be characterized as responders for both upper and
lower abdominal scores. Patients with ulcer-like symptoms
(13 patients) showed a more rapid decrease in symptoms
than other groups of patients. However, only 5 of these
ulcer-like patients could be considered responders according
to total symptom scores. Patients with GERD (18 patients)
showed a greater decrease in reﬂux-related symptoms when
compared with other patients—9/18 (50%) patients were
responders.
Out of 23 patients with upper-abdominal gas, 9 were
responders. Out of 15 patients with lower-abdominal gas, 6
were responders with parallel relief for ﬂatulence, abdominal
cramps, and abnormal bowel habits.
Out of 22 patients with irritable bowel syndrome, 8
were responders reporting the highest relief for abdominal
cramps. Out of 7 patients with constipation-predominant
IBS, 4 were responders, mostly due to a decrease in cramping
but also due to some improvement with constipation and
ﬂatulence. In diarrhea-predominant IBS 2 of 7 were respon-
ders, and in IBS-patients with the alternating bowel habit
subtype 3 out of 8 patients were categorized as responders
due to a improvement in cramps, diarrhea, and gas.
Patients with diarrhea (without typical IBS-symptoms)
had an impressive ratio of 5 responders out of 8. The sub-
group lower abdomen with predominant diarrhea com-
plaints improved its symptoms by an average of about 66%.
3.3. Tolerability. Out of the 90 participating patients, 29
reported 35 adverse events and 3 severe adverse events.
Thelatterwereexacerbationsofknownconcomitantdiseases
without causal relation to the gastrointestinal gel but led to
1 dropout. For 11 of the adverse events, a causal relation
was rated as possible (3 nausea, 1 abdominal spasm with
nausea, constipation, and ﬂatulence, 1 gastritis, 1 abdominal
distention, 1 pruritus ani, 1 worsening of heart burn, 1 di-
arrhea, 1 painful ﬂatulence, 1 gum bleeding) and 5 as proba-
bly related (1 pruritus, 1 hypogastric spasm, 1 sleep disorder,
1 nausea, 1 constipation). All of these gastrointestinal com-
plaints disappeared after a few days. 15 adverse events had an
improbablerelationshiptotreatment,7referringtogastroin-
testinal symptoms explained by acute viral gastrointestinal
infections. Some adverse drug reactions (20 patients) were
treated by reduction of dosage (9 patients) or by discontinu-
ing the therapy (11 patients).
4. Discussion
This uncontrolled observational study showed a signiﬁcant
and relevant improvement in gastrointestinal symptomGastroenterology Research and Practice 5
Per-protocol 62
Upper abdomen 34 Lower abdomen 32 Gas upper Abd.  29 Gas lower Abd.  22
Ulcus 13
Reflux/GERD 18
Dysmotility 3
IBS 22
Diarrhea-type 7
Obstipation-type 7
Alternating-type 8
Diarrhea 8 Obstipation 2
Figure 3: Patients subgroups according their predominant symptoms, patient numbers (n).
scores after 6 weeks of therapy with Silicea Gastrointestinal
Gel. Major part of patients reported a marked improve-
ment already after 3 weeks, but improvement continued
throughout the second half of the 6-week treatment phase. A
detailed questionnaire of gastrointestinal symptoms allowed
to deﬁne various subgroups and to characterize their symp-
tom reduction. In these subgroup analyses, the eﬀect of
symptom reduction could be observed in patients with very
diﬀerent symptom patterns of functional gastrointestinal
diseases from nonulcer dyspepsia to irritable bowel syn-
drome including even constipation-predominant IBS. Mean
total scores in all subgroups improved resulting in responder
rates over 30%. This is particularly remarkable since most of
the patients reported a long history of gastrointestinal com-
plaints resistant to many other therapies. It is also notable
that this relief was due to treatment with this rather simple
medicinal device silica gel. Good results were observed with
a wide variety of symptoms and symptom patterns showing
the possible ﬂexibility of treatment with silica gel.
The good tolerability was documented by adverse event
recording during the study. About 6% of patients reported
adverse reactions with a probable or possible relationship to
the test product. Most of these complaints were transient
gastrointestinal symptoms and could also be explained as a
kind of complex regulation process within the gastrointesti-
nal tract.
For functional gastrointestinal symptoms relevant pla-
cebo eﬀects are considered. A part of the eﬀect observed in
this study may be explained by placebo and regression-to-
mean eﬀects. Diﬀerences in the improvement of symptoms
between subgroups might be a hint that there is no uniform
placebo-eﬀect at least. When there would be at least one sub-
group with much lower response, this group might serve
as a pseudo-control—provided that these diﬀerences would
not be explained by diﬀerent placebo-responses according to
subgroups. The latter is not well investigated and variation
between study settings seems to be of major inﬂuence. In our
study we could roughly regard the responses in obstipation,
in which the mechanism of action of the product is unclear
at least as a possible placebo-eﬀect. The responses in other
subgroups are better than these in mean.
Especially in some of the subgroups, small sample sizes
are further limiting factors in this pilot study. Further inves-
tigation in controlled studies will be necessary to evaluate
theeﬀectofSiliceaGastrointestinalGelonspeciﬁcfunctional
gastrointestinal syndromes. The presented design of an open
study with detailed questionnaires for individual symptoms
is a useful tool for testing general gastrointestinal treatments
in order to understand which symptoms are most treatable.
This pilot study gives direction to future research.
5. Conclusion
SiliceaGastrointestinalGelmightbesuitableforusesextend-
ing beyond treatment of acute gastrointestinal disorders
caused by pathogens. Improvement of various gastrointesti-
nal symptoms in the course of treatment was documented
forallpatientsubgroups,especiallyinpatientssuﬀeringfrom
GERD and IBS. Diarrhea without cramps was the single
symptom which showed the most signiﬁcant improvements.
The maximum eﬀect was observed after several weeks of
treatment, with a marked improvement frequently notice-
able already after 3 weeks; a further improvement was seen
after6weeks,anditwasobservedthattherewasaprogressive
reduction of symptoms during treatment until the end of the
observation period.
It is remarkable that responder rates of approximately
30–50% were found in patients who have suﬀered for years
from functional gastrointestinal disorders which might be
regarded as therapy-refractory. These patients are highly
gratifying for such a simple and well-tolerated medical
device. We cannot exclude the results as mainly driven by
unspeciﬁc placebo-eﬀects.
Thus the results of this prospective, observational pilot
studyformavaluablebasisforconductingmorecomprehen-
sive controlled studies in patients with functional gastroin-
testinal diseases, focusing on diarrhea, GERD, and IBS.6 Gastroenterology Research and Practice
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